Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.

Literature DB >> 10508050

Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.

G A Pankuch¹, M R Jacobs, P C Appelbaum.

Abstract

Gatifloxacin pneumococcal, staphylococcal and enterococcal postantibiotic effects (PAEs) were 0.5 to 4.0 h, respectively. For Escherichia coli and Pseudomonas aeruginosa, PAEs were 2.2 to 4.8 h. Pneumococcal, staphylococcal, and enterococcal postantibiotic sub-MIC effects (PA-SMEs) (four times the MICs) were 3.7 to 8.6, 2.3 to 3.8, and 1.6 h, respectively, and E. coli and P. aeruginosa PA-SMEs were >/=9.6 and 4.4 h, respectively.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1999 PMID： 10508050 PMCID： PMC89526 DOI： 10.1128/AAC.43.10.2574

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

14 in total

1. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.

Authors: R Wise; N P Brenwald; J M Andrews; F Boswell
Journal: J Antimicrob Chemother Date: 1997-04 Impact factor: 5.790

Review 2. The post-antibiotic effect.

Authors: F M MacKenzie; I M Gould
Journal: J Antimicrob Chemother Date: 1993-10 Impact factor: 5.790

4. Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcus aureus strains.

Authors: Saichi Hoshi; Ken Kikuchi; Takashi Sasaki; Chie Sotozono; Shigeru Kinoshita; Keiichi Hiramatsu
Journal: Antimicrob Agents Chemother Date: 2008-05-19 Impact factor: 5.191

4 in total

Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.

1. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.

Review 2. The post-antibiotic effect.

3. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.

4. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.

5. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.

6. Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.

7. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.

8. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

9. Antibacterial properties of AM-1155, a new 8-methoxy quinolone.

10. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Review 1. Gatifloxacin: a review of its use in the management of bacterial infections.

2. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.

Review 3. Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

4. Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcus aureus strains.